Table 1 Comparison of S100A14 serum levels in patients according to the cancer pathological features
From: S100A14 serum level and its correlation with prognostic factors in breast cancer
Cancer characteristics | Cases, n (%) | Serum S100A14 (ng/ml) | P value* |
|---|---|---|---|
Tumor size (T) | |||
 1 | 18 (39.1) | 8.22 ± 1.03 | 0.07 |
 2 | 18 (39.1) | 7.78 ± 0.93 |  |
 3 | 6 (13.4) | 7.21 ± 1.06 |  |
 4 | 4 (8.7) | 7.56 ± 0.29 |  |
Lymph node involvement (N) | |||
 0 | 7 (15.2) | 8.48 ± 1.13 | 0.16 |
 1 | 16 (34.8) | 7.91 ± 1.23 |  |
 2 | 18 (39.1) | 7.67 ± 0.74 |  |
 3 | 5 (10.9) | 7.51 ± 0.29 |  |
Metastasis (M) | |||
 0 | 17 (37.0) | 7.28 ± 0.67 | 0.001 |
 1 | 29 (63.0) | 8.20 ± 0.99 |  |
Histopathological subtype | |||
 IDC | 34 (73.9) | 8.01 ± 1.01 | 0.10 |
 ILC | 12 (26.1) | 7.42 ± 0.82 |  |
Progesterone receptor (PR) | |||
 Positive | 28 (60.9) | 7.73 ± 0.98 | 0.34 |
 Negative | 18 (39.1) | 8.07 ± 0.99 |  |
Estrogen receptor (ER) | |||
 Positive | 24 (52.2) | 7.68 ± 1.06 | 0.19 |
 Negative | 22 (47.8) | 8.06 ± 0.88 |  |
Her2 receptor | |||
 Positive | 30 (65.2) | 7.76 ± 0.89 | 0.17 |
 Negative | 16 (34.8) | 8.05 ± 1.17 |  |